Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:category |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:George_Goldsmith
|
| gptkbp:clinicalTrialPhase |
psilocybin for depression
|
| gptkbp:country |
gptkb:United_Kingdom
|
| gptkbp:focusesOn |
psilocybin therapy
treatment-resistant depression |
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
gptkb:Ekaterina_Malievskaia
gptkb:George_Goldsmith |
| gptkbp:headquartersLocation |
gptkb:London,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Compass Pathways
|
| gptkbp:industry |
mental health care
psychedelic medicine |
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableProduct |
gptkb:COMP360
|
| gptkbp:numberOfEmployees |
100-200 (approximate, 2023)
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:CMPS
|
| gptkbp:website |
https://compasspathways.com/
|
| gptkbp:bfsParent |
gptkb:Peter_Thiel
|
| gptkbp:bfsLayer |
4
|